Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$71.21 USD

71.21
1,481,609

-0.73 (-1.01%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $71.19 -0.02 (-0.03%) 6:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (170 out of 252)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Omnicell (OMCL) New Buyout Expands Patient Engagement Suite

With the FDS Amplicare acquisition, Omnicell (OMCL) is expected to gain from several healthcare trends, banking on its offerings of digital technologies, SaaS solutions, and tech-enabled services.

NextGen's (NXGN) RCM Services Adopted by Coastal Orthopedics

NextGen's (NXGN) RCM Services aids Coastal Orthopedics to maintain its financial stability throughout the pandemic period.

Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio Now

Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.

Teleflex (TFX) Real-World Data Outcome Supports UroLift System

Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.

HSIC or COO: Which Is the Better Value Stock Right Now?

HSIC vs. COO: Which Stock Is the Better Value Option?

Syneos Health (SYNH) Enhances Clinical Trials With New Pact

Syneos Health (SYNH) recent partnership develops a more patient-centric travel experience, advances diversity and inclusion in clinical research.

Reasons to Hold on to AMN Healthcare (AMN) Stock for Now

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

SmileDirectClub (SDC) Struggles With New Markets, High Debt

SmileDirectClub's (SDC) escalating costs and expenses are putting pressure on the bottom line.

Glaukos (GKOS) Announces PMA Submission, Boosts iStent Platform

Glaukos (GKOS) submits PMA application to the FDA, which can enhance the company's deep portfolio of novel glaucoma surgical devices and sustained pharmaceuticals.

Stryker (SYK) Hits New 52-Week High: What's Driving It?

Investors are optimistic about Stryker's (SYK) strength in robotics and its diversified product portfolio.

TransMedics (TMDX) Receives FDA Nod for OCS Heart System

TransMedics' (TMDX) OCS Heart System is expected to enable broader use of donor hearts for transplantation in the United States.

Here's Why You Should Invest in Integer Holdings (ITGR) Now

Integer Holdings (ITGR) continues to gain traction from portfolio management.

Medtronic's (MDT) Emprint Ablation System Study Data Positive

Medtronic's (MDT) Emprint Ablation Catheter Kit received Breakthrough Device Designation status from the FDA in April 2021 and is currently in development.

Here's Why You Should Invest In Henry Schein (HSIC) Now

Investors are optimistic about Henry Schein (HSIC) owing to strong segmental performance and strategic buyouts and collaborations.

Masimo's (MASI) ORi Favored by New Study For ICU Patients' ETI

Masimo's (MASI) ORi is expected to provide early warnings of impending hypoxemia during the ETI procedure, thus aiding in averting any adverse incident.

Omnicell (OMCL) Opens New Software Development Center in India

Omnicell's (OMCL) new software development center in Bangalore, India, is expected to bolster the company's cloud-based solutions portfolio.

Abbott (ABT) Hits a New 52-Week High: What's Driving It?

Investors are optimistic about Abbott (ABT) on solid second-quarter performance and continued adoption of FreeStyle Libre worldwide.

LHC Group (LHCG) Closes Heart of Hospice Buyout, Expands Presence

LHC Group (LHCG) expands its hospice presence in five states with the completion of Heart of Hospice buyout.

Here's Why You Should Retain AmerisourceBergen (ABC) Stock Now

AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment.

Baxter (BAX) to Benefit From Hill-Rom Buyout: Here's How

Baxter's (BAX) latest acquisition is likely to accelerate its digitally-enabled connected care solutions across the care continuum and enhance patient services.

Masimo (MASI) Ties Up to Educate on Prescription Opioid Overuse

Masimo (MASI) partners with Penington Institute to increase awareness on overdose from prescription opioids.

QIAGEN (QGEN) to Join DAX Riding on Molecular Diagnostics Feat

QIAGEN (QGEN) is experiencing significant improvements in non-COVID areas of its molecular diagnostics portfolio.

Quidel's (QDEL) QuickVue OTC COVID-19 Test Now Widely Available

In-store and online availability of Quidel's (QDEL) QuickVue OTC COVID-19 Test is expected to meet the rising COVID-19 testing needs across the United States.

Why Is Henry Schein (HSIC) Down 0.8% Since Last Earnings Report?

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.